Literature DB >> 23009220

Regulatory T-cells in B-cell chronic lymphocytic leukemia: their role in disease progression and autoimmune cytopenias.

Deepesh P Lad1, Subhash Varma, Neelam Varma, Man Updesh Singh Sachdeva, Parveen Bose, Pankaj Malhotra.   

Abstract

Regulatory T-cells (Tregs) have been shown to be important for the balance of autoimmunity and oncogenesis. Tregs have a protective role in autoimmune diseases and conversely promote oncogenesis. Chronic lymphocytic leukemia (CLL) is unique in being at the cross-roads of oncogenesis and autoimmunity. We studied Tregs, defined as CD4+CD25(high)CD127(low)FOXP3+, in 32 treatment-naive patients with CLL. Our study shows that patients with CLL had a higher absolute Treg count than the control group (p < 0.001). A progressive increase of Tregs was noted in advanced stages of the disease (p < 0.001). The increase in absolute Treg count is more significant than the increase in percentage Tregs. The absolute Treg count appears to be more important in disease pathogenesis. The absolute Treg count was significantly higher in those patients having autoimmune cytopenias. There was an inverse correlation between lymphocyte doubling time and absolute Treg count (p = 0.03). The absolute Treg count may be used as a prognostic marker in CLL.

Entities:  

Mesh:

Year:  2012        PMID: 23009220     DOI: 10.3109/10428194.2012.728287

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  18 in total

Review 1.  CAR therapy for hematological cancers: can success seen in the treatment of B-cell acute lymphoblastic leukemia be applied to other hematological malignancies?

Authors:  Hollie J Pegram; Eric L Smith; Sarwish Rafiq; Renier J Brentjens
Journal:  Immunotherapy       Date:  2015       Impact factor: 4.196

2.  Regulatory T-cells in chronic lymphocytic leukemia: actor or innocent bystander?

Authors:  Giovanni D'Arena; Vittorio Simeon; Fiorella D'Auria; Teodora Statuto; Paola Di Sanzo; Laura De Martino; Aurelio Marandino; Michele Sangiorgio; Pellegrino Musto; Vincenzo De Feo
Journal:  Am J Blood Res       Date:  2013-01-17

3.  Trabectedin Reveals a Strategy of Immunomodulation in Chronic Lymphocytic Leukemia.

Authors:  Priyanka Banerjee; Ronghua Zhang; Cristina Ivan; Giovanni Galletti; Karen Clise-Dwyer; Federica Barbaglio; Lydia Scarfò; Miguel Aracil; Christian Klein; William Wierda; William Plunkett; Federico Caligaris-Cappio; Varsha Gandhi; Michael J Keating; Maria Teresa S Bertilaccio
Journal:  Cancer Immunol Res       Date:  2019-09-17       Impact factor: 11.151

4.  Clinical response to ibrutinib is accompanied by normalization of the T-cell environment in CLL-related autoimmune cytopenia.

Authors:  S Schliffke; N Akyüz; C T Ford; T Mährle; T Thenhausen; A Krohn-Grimberghe; S Knop; C Bokemeyer; M Binder
Journal:  Leukemia       Date:  2016-05-25       Impact factor: 11.528

5.  A Cross Sectional Study on T Cells and Subsets in Chronic Lymphocytic Leukemia and their Association with Clinical Phenotype.

Authors:  Mili Jain; Anushree Rai; Rashmi Kushwaha; Geeta Yadav; Sanjay Mishra; Shailendra Prasad Verma; Uma Shankar Singh; Anil Kumar Tripathi; Ashutosh Kumar
Journal:  Indian J Hematol Blood Transfus       Date:  2021-01-21       Impact factor: 0.915

6.  Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment.

Authors:  Iris de Weerdt; Tom Hofland; Renate de Boer; Johan A Dobber; Julie Dubois; Denise van Nieuwenhuize; Mehrdad Mobasher; Fransien de Boer; Mels Hoogendoorn; Gerjo A Velders; Marjolein van der Klift; Ester B M Remmerswaal; Frederike J Bemelman; Carsten U Niemann; Sabina Kersting; Mark-David Levin; Eric Eldering; Sanne H Tonino; Arnon P Kater
Journal:  Blood Adv       Date:  2019-09-10

7.  Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia.

Authors:  K A Rogers; A S Ruppert; A Bingman; L A Andritsos; F T Awan; K A Blum; J M Flynn; S M Jaglowski; G Lozanski; K J Maddocks; J C Byrd; J A Woyach; J A Jones
Journal:  Leukemia       Date:  2015-10-07       Impact factor: 11.528

Review 8.  Chronic lymphocytic leukaemia: could immunological tolerance mechanisms be the origin of lymphoid neoplasms?

Authors:  Ricardo García-Muñoz; Luis Llorente
Journal:  Immunology       Date:  2014-08       Impact factor: 7.397

9.  Identification and characterization of distinct IL-17F expression patterns and signaling pathways in chronic lymphocytic leukemia and normal B lymphocytes.

Authors:  Barbara Sherry; Preetesh Jain; Pui Yan Chiu; Ling Leung; Steven L Allen; Jonathan E Kolitz; Kanti R Rai; Jacquie Barrientos; Spencer Liang; Rachael Hawtin; Nicholas Chiorazzi
Journal:  Immunol Res       Date:  2015-12       Impact factor: 2.829

Review 10.  Autoimmune cytopenias in chronic lymphocytic leukemia.

Authors:  Giovanni D'Arena; Roberto Guariglia; Francesco La Rocca; Stefania Trino; Valentina Condelli; Laura De Martino; Vincenzo De Feo; Pellegrino Musto
Journal:  Clin Dev Immunol       Date:  2013-04-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.